

We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Oncology

Drug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights ¹	Collaborator/ Partner
mRNA	FixVac	BNT111	Advanced, R/R melanoma	██████████	██████████	██████████		Fully owned ²	
		BNT113	Metastatic/ R/R HPV16+ head and neck cancer	██████████	██████████	██████████			
		BNT116	1L metastatic NSCLC Advanced/metastatic NSCLC	██████████					
	iNeST	BNT122 (autogene cevumeran)	1L advanced melanoma	██████████	██████████	██████████		Collaboration	Genentech ³
			Adjuvant colorectal cancer	██████████	██████████	██████████			
			Adjuvant pancreatic ductal adenocarcinoma	██████████	██████████	██████████			
RiboMabs	BNT142	Multiple solid tumors (CD3×CLDN6)	██████████	██████████			Fully owned		
RiboCytokines	BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)	██████████				Fully owned		
Cell therapies	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)	██████████				Fully owned	
	Neoantigen-based T cells	BNT221	Refractory metastatic melanoma	██████████				Fully owned	
Protein-based therapeutics	Next-generation immune checkpoint modulators	BNT311 / GEN1046 (acasnlimab)	aPD(L)1-R/R metastatic NSCLC (PD-L1×4-1BB) Multiple solid tumors (PD-L1×4-1BB)	██████████	██████████	██████████		Collaboration	Genmab
		BNT312 / GEN1042	Multiple solid tumors (CD40×4-1BB) ⁴	██████████	██████████	██████████			
		BNT314 / GEN1059	Multiple solid tumors (EpCAM×4-1BB)	██████████	██████████	██████████			
		BNT315 / GEN1055	Multiple solid tumors (OX40)	██████████	██████████	██████████			
		BNT322 / GEN1056	Multiple solid tumors	██████████					
	Targeted cancer antibodies	BNT316 / ONC-392 (gotistobart)	aPD(L)1-R/R metastatic NSCLC (CTLA-4)	██████████	██████████	██████████	██████████	Collaboration	OncoC4
			Platinum-resistant ovarian cancer (CTLA-4)	██████████	██████████	██████████			
			Metastatic castration-resistant prostate cancer (CTLA-4)	██████████	██████████	██████████			
	Antibody-drug conjugates	BNT327/PM8002 + BNT325/DB-1305	Multiple solid tumors (CTLA-4)	██████████	██████████	██████████		Collaboration	Biotheus Duality Biologics
			Multiple solid tumors	██████████	██████████	██████████			
Antibody-drug conjugates	BNT321	Adjuvant pancreatic ductal adenocarcinoma (sLea)	██████████	██████████	██████████		Fully owned		
		Metastatic pancreatic cancer (sLea)	██████████						
	BNT323 / DB-1303	HR+/HER2-low metastatic breast cancer (HER2)	██████████	██████████	██████████	██████████	Collaboration	Duality Biologics	
		Multiple solid tumors (HER2)	██████████	██████████	██████████				
		Multiple solid tumors (B7H3)	██████████	██████████	██████████				
BNT325 / DB-1305	Multiple solid tumors (TROP2)	██████████	██████████	██████████					
BNT326 / YL202	Multiple solid tumors (HER3)	██████████				Collaboration	MediLink Therapeutics		
SMI ⁵	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)	██████████	██████████			Fully owned	

